Regeneron's Fianlimab-Cemiplimab Combination Misses Primary Endpoint in Phase 3 Melanoma Trial
核心洞察
Regeneron's Phase 3 trial evaluating fianlimab (LAG-3 (搜索) inhibitor) plus cemiplimab (PD-1 (搜索) inhibitor) in first-line metastatic melanoma (搜索) failed to achieve statistical significance for progression-free survival versus pembrolizumab monotherapy.
The high-dose combination showed a numeric improvement of 5.1 months in median progression-free survival (11.5 vs 6.4 months) but missed the p-value threshold with p=0.0627.
A head-to-head Phase 3 trial comparing the high-dose fianlimab combination against Opdualag (nivolumab and relatlimab-rmbw (搜索)) remains ongoing in the same patient population.
Regeneron Pharmaceuticals announced that its Phase 3 trial evaluating fianlimab, a LAG-3 (搜索) inhibitor, in combination with cemiplimab, a PD-1 (搜索) inhibitor, as first-line treatment for unresectable locally advanced or metastatic melanoma (搜索) failed to meet its primary endpoint of improved progression-free survival compared to pembrolizumab monotherapy.
Trial Results and Statistical Analysis
The randomized, double-blind Phase 3 trial enrolled 1,546 patients aged 12 years and older with unresectable locally advanced or metastatic melanoma (搜索) who had not received previous systemic treatment for advanced disease. The study compared two dose levels of the fianlimab-cemiplimab combination against pembrolizumab monotherapy.
The high-dose combination (1600 mg fianlimab and 350 mg cemiplimab every 3 weeks) demonstrated a median progression-free survival of 11.5 months (95% CI: 6.3, 16.8) compared to 6.4 months (95% CI: 4.4, 11.1) for pembrolizumab monotherapy. This represented a numeric improvement of 5.1 months, with a hazard ratio of 0.845 (95% CI: 0.709, 1.008) and a p-value of 0.0627, which did not reach statistical significance.
The low-dose combination (400 mg fianlimab and 350 mg cemiplimab every 3 weeks) showed a median progression-free survival of 9.6 months (95% CI: 6.2, 13.9) with a hazard ratio of 0.931 (95% CI: 0.773, 1.122) and p-value of 0.4661 compared to pembrolizumab.
Safety Profile and Ongoing Development
No new safety signals were identified with the fianlimab combination during the trial. The study also included a cemiplimab monotherapy arm (350 mg every 3 weeks) with 154 patients, which achieved a median progression-free survival of 6.3 months (95% CI: 4.0, 17.2), used to define the contribution of individual components rather than for statistical comparison.
Future Clinical Development
Despite missing the primary endpoint, Regeneron continues to advance the high-dose fianlimab combination in a separate Phase 3 head-to-head trial comparing it against Opdualag (nivolumab and relatlimab-rmbw (搜索)) in the same first-line unresectable or metastatic melanoma (搜索) setting. This ongoing study will provide additional data on the combination's potential therapeutic benefit.
The company plans to present detailed results from the completed trial at an upcoming medical meeting. The potential uses of fianlimab and cemiplimab described remain investigational, as safety and efficacy of this combination have not been evaluated by any regulatory authority.
Trial Design and Patient Population
The Phase 3 study randomized patients to receive either the high-dose fianlimab combination, low-dose fianlimab combination, pembrolizumab with placebo, or cemiplimab with placebo, all administered every 3 weeks. The trial's design allowed for comprehensive evaluation of both dose levels while maintaining appropriate controls for statistical comparison.